What is the Grant for Multiple Sclerosis Innovation?

  • The Grant for Multiple Sclerosis Innovation (GMSI) was launched at the 28th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in October 2012.
  • The first GMSI award ceremony took place at the 29th ECTRIMS congress in October 2013, with the announcement of four awardees.
  • The second GMSI award ceremony took place at the joint ACTRIMS-ECTRIMS congress in September 2014 with the announcement of five awardees.
  • Awardees of the 2015 grant will be announced during the 31 st ECTRIMS congress in October 2015.
  • The innovation grant will be awarded to support promising translational research projects by academic researchers to improve understanding of MS for the ultimate benefit of patients. Potential research topics that could be funded through the GMSI include MS pathogenesis, response to treatment and prediction of MS subtypes, identification of predictive or surrogate markers to allow better clinical decisions using currently available treatments as well as any potential new treatments, innovative patient support programmes, mobile health devices, or patient-reported outcomes. To be eligible to apply, applicants must have preliminary data to support their proposal.
  • A total grant of up to €1,000,000 will be awarded to one or more selected projects. The grant will build on the success of the Grant for Fertility Innovation (GFI), which has awarded grants that total up to €6,000,000 to translational research projects since 2010.
  • Applications are invited from around the world and will be reviewed by the Scientific Committee against the following criteria:
    • Relevance to clinical practice
    • Innovative research
    • Scientific rationale
    • Feasibility
    • Practical utility